Log in

NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Forecast & News

$0.71
-0.03 (-4.03 %)
(As of 02/19/2020 08:25 AM ET)
Today's Range
$0.71
Now: $0.71
$0.73
50-Day Range
$0.64
MA: $0.74
$0.92
52-Week Range
$0.28
Now: $0.71
$1.18
Volume46,744 shs
Average Volume130,634 shs
Market Capitalization$12.27 million
P/E RatioN/A
Dividend YieldN/A
Beta3.11
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$1.22 per share

Profitability

Net Income$-7,290,000.00

Miscellaneous

Employees14
Market Cap$12.27 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.


Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Shares of Cyclacel Pharmaceuticals reverse split before market open on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) released its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Cyclacel Pharmaceuticals.

What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

Media headlines about CYCC stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of -2.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cyclacel Pharmaceuticals.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 298,900 shares, a decline of 30.1% from the January 15th total of 427,900 shares. Based on an average daily trading volume, of 249,400 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.8% of the company's shares are short sold. View Cyclacel Pharmaceuticals' Current Options Chain.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include McEwen Mining (MUX), NovaBay Pharmaceuticals (NBY), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Novavax (NVAX), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), CTI BioPharma (CTIC) and Immunomedics (IMMU).

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.38%), Raymond James Financial Services Advisors Inc. (0.35%) and Virtu Financial LLC (0.29%). View Institutional Ownership Trends for Cyclacel Pharmaceuticals.

Which institutional investors are selling Cyclacel Pharmaceuticals stock?

CYCC stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Cyclacel Pharmaceuticals.

Which institutional investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. View Insider Buying and Selling for Cyclacel Pharmaceuticals.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.71.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $12.27 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is http://www.cyclacel.com/.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  349
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel